The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.

Abstract

Cerebral metastases from melanoma are correlated with a poor prognosis. Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%. The present study evaluated the efficacy and toxicity of temozolomide-based… (More)

Topics

Cite this paper

@article{Bafaloukos2004TheEO, title={The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.}, author={Dimitrios I Bafaloukos and Dimosthenis A Tsoutsos and Georges Fountzilas and Helen Linardou and Christos Christodoulou and Haralambos P. Kalofonos and Erangelos Briassoulis and Petros N. Panagiotou and Helen Hatzichristou and Helen J. Gogas}, journal={Melanoma research}, year={2004}, volume={14 4}, pages={289-94} }